GlassScriptPhysician profile
Susan Davila
NPI 1902885072
$3,548.56
in general payments reported to CMS, 2019-2025
30 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $470 · 2021: $348 · 2022: $743 · 2023: $810 · 2024: $371 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.00 |
| Education | $184.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $469.63 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $368.62 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $356.33 | 2021-2025 | |
| Coopersurgical, INC. | $283.86 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $189.44 | 2022-2025 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Therapeuticsmd, INC. | $181.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.56 | 2019-2025 | |
| Allergan, INC. | $165.28 | 2019-2020 | |
| Scynexis, INC. | $154.09 | 2022 | |
| Coloplast Corp | $152.71 | 2020 | |
| Avion Pharmaceuticals | $123.68 | 2019-2021 | |
| Pfizer INC. | $119.34 | 2019-2025 | |
| Exeltis, USA INC. | $97.12 | 2021-2023 | Slynd |
| Aspira Women'S Health INC | $93.16 | 2020 | |
| Exact Sciences Corporation | $90.17 | 2023-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $72.96 | 2019-2020 | |
| Smith+Nephew, INC. | $69.14 | 2022-2024 | Pico 14 |
| Millicent US INC | $65.58 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Organon LLC | $60.16 | 2023-2024 | Nexplanon |
| Myovant Sciences INC. | $56.57 | 2021-2022 | |
| Shield Therapeutics INC | $30.67 | 2023-2024 | Accrufer |
| Amag Pharmaceuticals, INC. | $28.86 | 2019 | |
| Mission Pharmacal Company | $26.40 | 2023 | Citranatal |
| Mylan Pharmaceuticals INC. | $21.87 | 2022 | |
| Novo Nordisk INC | $21.75 | 2023 | Wegovy |
| Boston Scientific Corporation | $20.39 | 2020 | |
| Sumitomo Pharma America, INC. | $17.86 | 2023 | Myfembree |
| Lilly USA, LLC | $15.00 | 2025 | Zepbound |
| Amgen INC. | $13.00 | 2019 | |
| Covidien LP | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Davila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.